Novo Nordisk

News

Novo Nordisk follows Lilly into DTC obesity drug market

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

Compounders cast adrift after semaglutide shortage ends

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

News

When licensing deals go bad - Novo sues KBP Bio for $830m

Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.

News

First biosimilar fast-acting insulin reaches US market

Sanofi has claimed FDA approval for the first biosimilar of Novo Nordisk's rapid-acting insulin analogue Novolog.

News

Small study finds GLP-1 drug can curb excess alcohol use

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.

News

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."

Novo Nordisk follows Lilly into DTC obesity drug market

Compounders cast adrift after semaglutide shortage ends

When licensing deals go bad - Novo sues KBP Bio for $830m

First biosimilar fast-acting insulin reaches US market

Small study finds GLP-1 drug can curb excess alcohol use

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks